Gel Column Agglutination Test System Market

The global gel column agglutination test system market was valued at USD 340.5 million in 2025 and is estimated at USD 361.8 million in 2026. The market is projected to reach USD 587.3 million by 2034, representing a 6.2% CAGR during 2026–2034.

Gel column agglutination test systems are immunohematology platforms used for blood grouping, antigen typing, antibody screening, antibody identification, compatibility testing and direct antiglobulin testing. The technology separates agglutinated from non-agglutinated red blood cells within gel-filled microcolumns, improving standardization compared with conventional tube agglutination.

The addressable market is supported by the scale and safety requirements of global transfusion systems. WHO reported 120.4 million blood donations worldwide and continues to emphasize standardized testing, haemovigilance and quality-assured blood systems. Gel-card technology fits these priorities by improving repeatability, reducing subjective interpretation and supporting automated data management.

Automation is moving the market beyond manual cards toward integrated analyzers. In May 2026, FDA approved Diagnostic Grifols Erytra Eflexis for automated blood grouping and antibody testing using DG Gel 8 cards and also approved the ORTHO Optix Reader for automated interpretation of ID-MTS gel-card reactions. These approvals reinforce the shift toward digital image processing, laboratory information system connectivity and higher-throughput transfusion workflows.

Source: WHO blood safety and availability; FDA Erytra Eflexis and ORTHO Optix approvals; FDA DG Gel Cards.

The study defines the global gel column agglutination test system market market by the equipment, application, end-user and technology boundaries listed below. The scope is structured to keep market sizing consistent with the commercial systems and services included in the syndicated study.

Global transfusion activity creates recurring testing demand

Every blood donation and transfusion episode requires a series of compatibility, grouping and antibody-screening steps that sustain consumable demand.

Automation reduces interpretation variability

Digital readers and automated analyzers standardize reaction grading and minimize manual transcription or subjective reading.

Gel cards create durable recurring revenue

Installed analyzers generate repeat purchases of cards, reagents, controls and accessories, creating attractive annuity-like consumable streams.

Capital cost remains a barrier for smaller laboratories

Fully automated immunohematology systems require meaningful up-front investment, service support and a throughput level sufficient to justify installation.

Blood-safety policy supports modernization

National blood programs increasingly prioritize traceability, quality systems, haemovigilance and standardized laboratory processes.

Fully automated gel systems are gaining share

Large laboratories are replacing manual or semi-manual workflows with analyzers that integrate incubation, centrifugation, imaging and interpretation.

Digital image interpretation is becoming a core feature

Automated grading improves consistency and enables remote review, audit trails and standardized result storage.

LIS connectivity is moving from premium to expected

Hospital laboratories increasingly require bidirectional data exchange to reduce transcription errors and support traceability.

Compact automation is expanding the addressable market

Mid-volume blood banks are adopting smaller analyzers that provide automation without the footprint of large central-lab systems.

Consumable menus are broadening

Suppliers continue adding card configurations for ABO/Rh typing, antibody screening, phenotyping, DAT and compatibility testing.

Gel column agglutination combines immunologic reactions with density-based separation inside microcolumns to provide stable, visually interpretable endpoints.

By type, the market is segmented into manual, semi-automated and fully automated systems. Fully automated systems are the leading growth category because they provide integrated card processing and result interpretation.

Fully automated systems should gain the largest incremental value, while manual and semi-automated systems retain relevance in lower-throughput settings.

By application, the market is segmented into blood grouping and crossmatching, antibody screening and identification, direct antiglobulin testing, and other immunohematology tests. Blood grouping and crossmatching remain the largest routine application.

Blood grouping and crossmatching will remain the largest application, while antibody identification supports high-value specialist testing.

By product, the market is segmented into instruments or analyzers, gel cards and reagents, and controls or accessories. Gel cards and reagents form the largest recurring-revenue segment.

Gel cards and reagents should remain the largest lifetime-revenue pool, while analyzer placements drive customer acquisition and platform expansion.

By end user, the market is segmented into hospitals, blood banks or blood centers, and diagnostic laboratories. Hospitals and blood banks account for the largest installed base.

Hospitals and blood banks will remain the dominant end users, while reference laboratories create demand for broader test menus and specialist workflows.

By throughput, the market is segmented into low-, medium- and high-throughput systems. High-throughput systems lead value, while medium-throughput platforms address the broadest laboratory base.

High-throughput systems will remain the leading value segment, while medium-throughput automation should support the widest new-placement opportunity.

Regional demand reflects blood-service modernization, transfusion volumes and laboratory automation. North America is the largest current market, while Asia-Pacific provides the strongest long-term expansion opportunity.

Gel-column systems operate within tightly controlled transfusion-medicine environments where reagent performance, analyzer validation and traceability are central to patient safety.

Source: FDA QHR classification; FDA QHS classification; FDA 2026 approvals; WHO 2026–2030 action framework.

Competition is moderately concentrated around major transfusion-diagnostics companies with proprietary cards, analyzers and reagent menus. Customer retention is strengthened by instrument placement, training and recurring consumable use.

• Diagnostic Grifols
• QuidelOrtho
• Bio-Rad Laboratories
• Werfen / Immucor
• DiaSorin
• Regional Immunohematology Suppliers

Source: FDA 2026 biological device approvals; WHO blood-safety report; WHO action framework.

The global gel column agglutination test system market market is projected to grow from USD 361.8 million in 2026 to USD 587.3 million by 2034, at a 6.2% CAGR during 2026–2034. Growth is expected to be supported by blood-bank automation, recurring gel-card consumption, digital image interpretation and broader transfusion-safety investment. Fully automated and medium-to-high-throughput platforms should capture the strongest value growth.

The study is structured to support strategy, market-entry assessment, portfolio planning, competitive benchmarking and commercial opportunity analysis across the global gel column agglutination test system market landscape.